A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)

NCT05066646 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: CT103A

Sponsor

Nanjing IASO Biotechnology Co., Ltd.